Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiomyopathy
Pharma
Alnylam's Amvuttra off to promising start in ATTR-CM
After BridgeBio blew away analyst projections for its new ATTR-CM drug Attruby, Alnylam countered with positive news for its Amvuttra.
Kevin Dunleavy
May 1, 2025 11:46am
BMS' Camzyos falls short in bid to widen eligible patient pool
Apr 15, 2025 11:42am
Alnylam's Amvuttra wins key cardiomyopathy FDA nod
Mar 20, 2025 7:40pm
JPM25: BridgeBio's cardiomyopathy drug is off to a roaring start
Jan 13, 2025 9:40pm
Look out, Pfizer: BridgeBio gains 'best-case' FDA nod for Attruby
Nov 25, 2024 7:59am
Alnylam sees Amvuttra as potential standard of care in ATTR-CM
Aug 30, 2024 10:06am
